A hypoxia-specific and mitochondria-targeted anticancer theranostic agent with high selectivity for cancer cells

Area of Science:

• Biomedical Engineering
• Molecular Imaging
• Cancer Therapeutics

Background:

• Hypoxia is a hallmark of solid tumors, often associated with treatment resistance.
• Mitochondria are crucial organelles involved in cellular metabolism and apoptosis.
• Theranostic agents offer simultaneous diagnosis and therapy, improving treatment outcomes.

Purpose of the Study:

• To develop and characterize a novel mitochondria-targeted theranostic compound, HMX-1.
• To evaluate the hypoxia-activated fluorescence and mitochondria-targeting capabilities of HMX-1.
• To assess the in vitro and in vivo anti-cancer efficacy of HMX-1.

Main Methods:

• Synthesis and characterization of the HMX-1 compound.
• Cellular uptake and fluorescence imaging studies under normoxic and hypoxic conditions.
• In vitro cytotoxicity assays using cancer cell lines.
• In vivo anti-tumor efficacy studies in animal models.

Main Results:

• HMX-1 demonstrated excellent solubility and selective activation under hypoxic conditions.
• The compound exhibited strong mitochondria-targeting ability with a significant increase in fluorescence intensity upon activation.
• HMX-1 showed potent anti-cancer efficiency in both in vitro and in vivo experiments.

Conclusions:

• HMX-1 represents a promising hypoxia-activated, mitochondria-targeted theranostic agent for cancer therapy.
• Its ability to target mitochondria and respond to hypoxia offers potential for improved cancer diagnosis and treatment.
• Further investigation is warranted to explore its clinical applicability.